| # | Drug | Count |
|---|---|---|
| 0 | RIBAVIRIN | 2 |
| 1 | SOFOSBUVIR | 2 |
| 2 | BEVACIZUMAB | 1 |
| 3 | BUPROPION HYDROCHLORIDE | 1 |
| 4 | GLECAPREVIR AND PIBRENTASVIR | 1 |
| 5 | LEDIPASVIR AND SOFOSBUVIR | 1 |
| 6 | MITAPIVAT | 1 |
| 7 | VELPATASVIR AND SOFOSBUVIR | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | MITAPIVAT | 1 | 0.0008 |
| 1 | SOFOSBUVIR | 2 | 0.0001 |
| 2 | GLECAPREVIR AND PIBRENTASVIR | 1 | 0.0001 |
| 3 | VELPATASVIR AND SOFOSBUVIR | 1 | 0.0001 |
| 4 | LEDIPASVIR AND SOFOSBUVIR | 1 | 0.0001 |
| 5 | RIBAVIRIN | 2 | 0.0000 |
| 6 | BUPROPION HYDROCHLORIDE | 1 | 0.0000 |
| 7 | BEVACIZUMAB | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Pyruvate Kinase Activator [EPC] | 1 | 0.0008 |
| 1 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] | 4 | 0.0001 |
| 2 | Hepatitis C Virus NS5A Inhibitor [EPC] | 3 | 0.0001 |
| 3 | Hepatitis C Virus NS3/4A Protease Inhibitor [EPC] | 1 | 0.0001 |
| 4 | Nucleoside Analog Antiviral [EPC] | 2 | 0.0000 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1 | 0.0000 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1 | 0.0000 |